Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

Leukemia volume 31, pages 495–498 (2017)Cite this article

Subjects

The Philadelphia-chromosome negative chronic myeloproliferative neoplasms (MPNs) are acquired cancer diseases that arise due to mutations in the hematopoietic stem cells in the bone marrow. MPNs comprise essential thrombocythemia, polycythemia vera and primary myelofibrosis, which are neoplastic diseases of the hematopoietic stem cells.1

Several studies have documented a dysregulation of the immune system in MPN.2, 3 Interferon-alpha is a potent immunostimulatory drug4 used to treat MPNs, and induces a considerable decrease in the JAK2-mutated allele burden in a substantial part of patients.5 Studies have revealed marked changes in the immune phenotype of MPN patients treated with interferon-alpha, which suggests that this drug reinstates the defective tumor immune surveillance in MPN.6 These studies opened the avenue for further immune cell studies aiming at creating a platform for vaccination in MPNs. Notably, Xiong and coworkers described anti-tumor humoral immune reactions towards two immunogenic antigens in a subset of MPN, although there was no difference in expression of antigens between diseased cells and normal cells.7

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Campbell PJ, Green AR . The myeloproliferative disorders. N Engl J Med 2006; 355: 2452–2466.

    Article  CAS  Google Scholar 

  2. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A . Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356–1363.

    Article  CAS  Google Scholar 

  3. Skov V, Riley CH, Thomassen M, Larsen TS, Jensen MK, Bjerrum OW et al. Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma 2013; 54: 2269–2273.

    Article  CAS  Google Scholar 

  4. Parker BS, Rautela J, Hertzog PJ . Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 2016; 16: 131–144.

    Article  Google Scholar 

  5. Silver RT, Kiladjian J-J, Hasselbalch HC . Interferon and the treatment of polycythaemia vera, essential thrombocytemia and myelofibrosis. Exp Hematol 2013; 6: 1–10.

    Article  CAS  Google Scholar 

  6. Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L et al. Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. Eur J Haematol 2016; 97: 83–92.

    Article  CAS  Google Scholar 

  7. Xiong Z, Yan Y, Liu E, Silver RT, Verstovsek S, Yang F et al. Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. Clin Immunol 2007; 122: 279–287.

    Article  CAS  Google Scholar 

  8. Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Ph D et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

    Article  CAS  Google Scholar 

  9. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T . Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14: 135–146.

    Article  CAS  Google Scholar 

  10. Rammensee H-G, Bachmann J, Emmerich N, Bachor OA, Stevanovic S . SYFPEITHI: database for MHC ligands and peptide motifs. Available at: www.syfpeithi.de (accessed 30 October 2014).

  11. Munir S, Andersen GH, Met Ö, Donia M, Frøsig TM, Larsen SK et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res 2013; 73: 1764–1776.

    Article  CAS  Google Scholar 

  12. Moodie Z, Price L, Gouttefangeas C, Mander a, Janetzki S, Löwer M et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010; 59: 1489–1501.

    Article  CAS  Google Scholar 

  13. Quentmeier H, MacLeod RaF, Zaborski M, Drexler HG . JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006; 20: 471–476.

    Article  CAS  Google Scholar 

  14. Met Ö, Balslev E, Flyger H, Svane IM . High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res Treat 2011; 125: 395–406.

    Article  CAS  Google Scholar 

  15. Jedidi A, Marty C, Oligo C, Jeanson-Leh L, Ribeil JA, Casadevall N et al. Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood 2009; 114: 1842–1851.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank laboratory technician Merete Jonassen for outstanding help with the experiments and for helping MOH to perform the assays. This study was supported in part by grant from Danish Cancer Society to HCH (grant number R90-A6143-14-S2).

Author information

Authors and Affiliations

  1. Department of Hematology, Zealand University Hospital, Roskilde, Denmark

    M O Holmström, C Riley & H C Hasselbalch

  2. Department of Hematology, Center for Cancer Immune Therapy, Copenhagen University Hospital Herlev, Herlev, Denmark

    M O Holmström, M D Hjortsø, S M Ahmad, Ö Met, E Martinenaite, P Straten, I M Svane & M H Andersen

  3. Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark

    Ö Met & I M Svane

  4. Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark

    M H Andersen

Authors
  1. M O Holmström
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M D Hjortsø
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S M Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ö Met
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Martinenaite
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Riley
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Straten
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I M Svane
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H C Hasselbalch
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M H Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M H Andersen.

Ethics declarations

Competing interests

MOH, HCH and MHA have filed a patent regarding the JAK2V617F mutation as a target for cancer immune therapy. The patent has been transferred to University Hospital Zealand, Zealand Region and Copenhagen University Hospital at Herlev, Capital Region according to Danish Law concerning inventions made at public research institutions. The remaining authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holmström, M., Hjortsø, M., Ahmad, S. et al. The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms. Leukemia 31, 495–498 (2017). https://doi.org/10.1038/leu.2016.290

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.290

This article is cited by

Search

Advanced search

Quick links